Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review

由 Calverley, Peter, Rogliani, Paola, Papi, Alberto
發表在 Drug Saf (2020)

Rate of Decline of FEV(1) as a Biomarker of Survival?

由 Papi, Alberto, Beghé, Bianca, Fabbri, Leonardo M.
發表在 Am J Respir Crit Care Med (2021)

Models of Respiratory Infections: Virus-Induced Asthma Exacerbations and Beyond

由 Saturni, Sara, Contoli, Marco, Spanevello, Antonio, Papi, Alberto
發表在 Allergy Asthma Immunol Res (2015)

The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study

由 Singh, Dave, Vezzoli, Stefano, Petruzzelli, Stefano, Papi, Alberto
發表在 Int J Chron Obstruct Pulmon Dis (2017)

Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study

由 Papi, Alberto, Di Stefano, Andrea F. D., Radicioni, Milko
發表在 Adv Ther (2020)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD

由 Scichilone, Nicola, Benfante, Alida, Morandi, Luca, Bellini, Federico, Papi, Alberto
發表在 Patient Relat Outcome Meas (2014)

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease

由 Singh, Dave, Corradi, Massimo, Spinola, Monica, Petruzzelli, Stefano, Papi, Alberto
發表在 NPJ Prim Care Respir Med (2016)

Mechanisms of rhinovirus-induced asthma

由 Papadopoulos, Nikolaos G, Papi, Alberto, Psarras, Stelios, Johnston, Sebastian L
發表在 Paediatr Respir Rev (2004)

Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations

由 Nicolini, Gabriele, Scichilone, Nicola, Bizzi, Andrea, Papi, Alberto, Fabbri, Leonardo M
出版 2008

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

由 Vanfleteren, Lowie, Fabbri, Leonardo M, Papi, Alberto, Petruzzelli, Stefano, Celli, Bartolome
發表在 Int J Chron Obstruct Pulmon Dis (2018)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA

由 Singh, Dave, Fabbri, Leonardo M, Vezzoli, Stefano, Petruzzelli, Stefano, Papi, Alberto
發表在 Int J Chron Obstruct Pulmon Dis (2019)

Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease

由 Pascoe, Steven J., Papi, Alberto, Midwinter, Dawn, Lettis, Sally, Barnes, Neil
發表在 Respir Res (2019)

Models of infection and exacerbations in COPD

由 Papi, Alberto, Contoli, Marco, Gaetano, Caramori, Mallia, Patrick, Johnston, Sebastian L
發表在 Curr Opin Pharmacol (2007)

Management of chronic refractory cough in adults

由 Visca, Dina, Beghè, Bianca, Fabbri, Leonardo Michele, Papi, Alberto, Spanevello, Antonio
發表在 Eur J Intern Med (2020)

New drugs targeting Th2 lymphocytes in asthma

由 Caramori, Gaetano, Groneberg, David, Ito, Kazuhiro, Casolari, Paolo, Adcock, Ian M, Papi, Alberto
出版 2008

A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with...

由 Virchow, J. Christian, Rodriguez-Roisin, Roberto, Papi, Alberto, Shah, Tushar P., Gopalan, Gokul
發表在 BMC Pulm Med (2016)

Treatment strategies for asthma: reshaping the concept of asthma management

由 Papi, Alberto, Blasi, Francesco, Canonica, Giorgio Walter, Morandi, Luca, Richeldi, Luca, Rossi, Andrea
發表在 Allergy Asthma Clin Immunol (2020)

ICS/formoterol in the management of asthma in the clinical practice of pulmonologists: an international survey on GINA strategy

由 Cruz, Álvaro A., Barile, Sara, Nudo, Elena, Brogelli, Laura, Guller, Patricia, Papi, Alberto
發表在 Asthma Res Pract (2021)

Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial

由 Papi, Alberto, Nicolini, Gabriele, Crimi, Nunzio, Fabbri, Leonardo, Olivieri, Dario, Rossi, Andrea, Paggiaro, Pierluigi
出版 2012

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD

由 Papi, Alberto, Jones, Paul W, Dalvi, Prashant S, McAulay, Kirsten, McIver, Tammy, Dissanayake, Sanjeeva
發表在 Int J Chron Obstruct Pulmon Dis (2015)